We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




PET May Reduce, Eliminate Prolonged Drug Development Trials

By Biotechdaily staff writers
Posted on 17 May 2005
Various recent studies assessing small animal imaging with the use of positron emission tomography (PET) are providing new insights into the treatment of human disease.

A big advantage of small animal imaging "is the ability to carry out many studies at various time points with the same animal,” remarked Michael J. More...
Welch, Ph.D., co-author of a paper published in the April 2005 issue of the Journal of Nuclear Medicine. Dr Welch is co-director of the division of radiological sciences at Washington University's Mallinckrodt Institute of Radiology (St. Louis, MO, USA). He explained that research on the same living animal can be stretched over a period of time, allowing scientists to track the development of disease in one subject and to assess the effects of treatments of disease progression and outcome.

Vital information can be obtained noninvasively, quantitatively, and repeatedly in the same animal, according to Dr. Welch. With PET imaging of small animals, one can very quickly assess new radiopharmaceutical agents using a small number of animals and possibly eliminate the need for biopsies, extending an animal's life.

PET offers a noninvasive look into an individual's living biology as it monitors a variety of biologic mechanisms including metabolism, gene expression, and drug activity. A smaller version of a PET scanner was developed to image small animals in the same manner. Small animals, in particular mice, play an essential role in the study of human biology and disease. Mice have almost the same set of genes as humans, which can lead to a further understanding about the function of many genes shared by both, leading to a further insights into the diagnosis of disorders such as Parkinson's and Alzheimer's disease, epilepsy, cardiovascular disease, and cancer.

Small animal imaging can considerably reduce the practical assessment time for therapeutic agents, potentially hastening the way for more innovative drug therapy for patients, according to Dr. Welch. He estimates that there may be as many as 12,000 private and academic animal imaging laboratories in the world today, and that more than 200 may conduct small animal PET scanning routinely.

Dr. Welch and coworkers are also studying the effect of cancer therapies on tumor function and are performing cardiac studies to examine drugs that reverse the disease process in animals.




Related Links:
Mallinckrodt Institute of Radiology >>

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
HPV Test
Allplex HPV28 Detection
New
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.